The Impact of Transitioning From Guaiac-Fecal Occult Blood Testing to Fecal Immunochemical Testing in a Canadian Colon Cancer Screening Program. Issue 4 (11th April 2019)

• Record Type: Journal Article
• Authors: Sultanian, Richard; Du, Lillian; Moysey, Barbara; Morse, Amy; Veldhuyzen van Zanten, Sander; Montano-Loza, Aldo J
• Is Part Of: Journal of the Canadian Association of Gastroenterology. Volume 3:Issue 4(2020)
• Page Start: 177
• Page End: 184
• Publication Date: 2019-04-11
• Subjects: Adenoma detection -- Colorectal cancer -- Colon cancer screening -- Fecal immunochemical testing -- Guaiac-based fecal occult blood testing -- Polyp detection; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1093/jcag/gwz009
• Languages: English
• ISSNs: 2515-2084

Abstract

Abstract: Objectives: To determine the impact of transitioning from guaiac-based fecal occult blood testing (gFOBT) to fecal immunochemical testing (FIT) on the detection rate of adenomas, advanced adenomas (AA) and colorectal cancer (CRC). Background: Recently, the health region in Edmonton, Alberta switched from gFOBT to FIT for CRC screening. Study: A retrospective analysis of all patients, aged 50 to 74 years, referred for colonoscopy from January 1, 2013 to December 31, 2014 due to a positive gFOBT (at least one of three samples positively using the guaiac-based Hemoccult II SENSA in 2013) or FIT (≥75 µg/g of stool, using the Polymedco OC FIT-CHEK in 2014). The primary outcomes were the number of colon cancers, AA and adenomas detected in 2013 and 2014. A comparison between the two tests was also made for the composite outcome of detection of either AA or CRC. Results: Six hundred and forty-nine patients underwent colonoscopy due to a positive gFOBT in 2013, and 2167 patients for a positive FIT in 2014. FIT compared with gFOBT detected more CRC (67 compared with 34), AA (770 compared with 147) and adenomas (1575 versus 320). By multivariable regression analysis adjusted for different demographics and endoscopic metrics, positive FIT was independently associated with higher adenoma detection rate (odds ratio [OR] 2.62; 95% confidence interval [CI] 2.13 to 3.21, P < 0.001), AA detection rate (OR 1.83, 95% CI 1.43 to 2.33, P < 0.001), and the composite outcome of AA and CRC (OR 2.04, 95% CI 1.60 to 2.59, P < 0.001). Conclusions: Adoption of FIT compared with gFOBT led to higher detection of colon cancer, AA and adenomas.